Translational Breast Cancer Research最新文献_第6页

Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study margetuximab +化疗vs.曲妥珠单抗+化疗在中国her2阳性晚期转移性乳腺癌患者中的疗效和安全性:来自一项随机、开放标签、多中心、II期桥接研究的结果

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-22-35

Qingyuan Zhang, Q. Ouyang, Wei Li, J. Chiu, Ming Yan, Yen-Shen Lu, Sanyuan Sun, Huiping Li, Yingying Du, Xujuan Wang, T. Sun, Yongmei Yin, haibo wang, F. Ye, K. Shen, Jingfen Wang, Yueyin Pan, Shusen Wang, Jin Yang, Xiaohong Wu, M. Dai, Jing Cheng, Y. Teng, Fang Su, Xin-hong Wu, Jingdong He, P. Fu, Lulu Yang, Yuan Xin, Xiaojian Wang, Zefei Jiang

引用次数: 0

Reduction in tumor grade and Ki-67 in postmenopausal patient with node-positive invasive ductal carcinoma following combination hormone replacement therapy cessation: a case report 停止联合激素替代治疗后绝经后淋巴结阳性浸润性导管癌患者肿瘤分级和Ki-67降低1例报告

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-22-26

C. King, Monika K Masanam, A. Maini, Clint M. Merritt, Kenneth L. Fan, I. Greenwalt

引用次数: 0

2021 updates in postoperative radiotherapy section of Chinese Society of Clinical Oncology Breast Cancer guideline 2021年中国临床肿瘤学会乳腺癌指南术后放疗部分更新

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/tbcr-21-15

Lu Cao, Jun Zhang, Jiayi Chen, Zefei Jiang

引用次数: 1

St. Gallen 2021 Chinese expert perspective of optimal regional management 圣加仑2021中国专家视角下的最佳区域管理

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/tbcr-21-16

B. Cong, Yongsheng Wang

引用次数: 0

Neoadjuvant chemotherapy choices from population selection to regimen design: the St. Gallen International Expert Consensus Conference 2021 从人群选择到方案设计的新辅助化疗选择:2021年圣加仑国际专家共识会议

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/tbcr-21-14

Qianqian Guo, Qianjun Chen

引用次数: 0

Introduction to the key contents of the Chinese Society of Breast Surgery Practice Guideline 2021 《中国乳房外科学会实践指南2021》重点内容介绍

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/tbcr-21-8

H. Xiang, Qian Liu, Yin-hua Liu

引用次数: 0

We are on the right road | A brief history of breast cancer guidelines in China 我们走在正确的道路上|中国乳腺癌指南简史

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/tbcr-2021-1

Jessica Liao

{"title":"We are on the right road | A brief history of breast cancer guidelines in China","authors":"Jessica Liao","doi":"10.21037/tbcr-2021-1","DOIUrl":"https://doi.org/10.21037/tbcr-2021-1","url":null,"abstract":"On a spring day in 2006, proposed by Dr. Yan Sun, a famous oncologist in China, the US National Comprehensive Cancer Network (NCCN) guidelines were introduced into China, kicking off the efforts of Chinese scientists and clinicians in developing China’s guidelines on tumors. On another spring day in 2011, with invaluable input and insight from top Chinese oncologists dedicated to advancing cancer care in China, the first Guidelines of the Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Melanoma were published. In April 2021, CSCO had issued 23 clinical guidelines for managing tumors, including breast cancer, colorectal cancer, ovarian cancer, nasopharyngeal cancer, and differentiated thyroid cancer. Other 10 guidelines are also on the way and are scheduled to be published in 2021. Success is never easy. The 5-year period from 2006 to 2011 witnessed the efforts and persistence of generations of Chinese oncologists to introduce, adapt, and self-develop clinical practice guidelines for the treatment of tumors. The leadership of our farsighted predecessors and the executive ability of front-line clinicians fighting against tumors are the keys to the success of establishing guidelines with Chinese characteristics. The full respect for science and norms, and the commitment and cohesion of every medical worker in China, have led to several guidelines and updates. Despite the arduousness, Chinese oncologists are still firmly advancing on this broad road. Among them is Prof. Zefei Jiang (Figure 1), one of the contributors to the NCCN Clinical Practice Guidelines for Breast Cancer. The first Chinese expert voted on the podium of the St Gallen International Consensus Guidelines in Early-stage Breast Cancer, the Chief of the expert group of the CSCO Breast Cancer Guidelines, Vice President and Secretary-General of CSCO, and Chairman of the CSCO Breast Cancer Committee. His career followed the development of China's breast cancer guidelines.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124881888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021 2021年圣加仑国际乳腺癌大会关于全身治疗的专家综述

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/tbcr-21-7

Mingxi Lin, Yizi Jin, Jian Zhang

引用次数: 2

Updated interpretation for early breast cancer in The Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines 中国临床肿瘤学会乳腺癌(CSCO BC)指南对早期乳腺癌的最新解释

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/TBCR-21-13

Bo Shen, Kun Wang, Zefei Jiang

引用次数: 1

Development and validation of a nomogram for predicting the status of estrogen receptor-low-positive breast cancer 雌激素受体低阳性乳腺癌状态的nomogram预测方法的开发与验证

Translational Breast Cancer Research Pub Date : 2021-07-31 DOI: 10.21037/TBCR-21-12

Zhanli Jia, Shuyao Niu, Xinle Wang, Siyi Wu, Jinze Li, Meng Han, Yueping Liu

引用次数: 0